Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E plus C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
Tabernero, J., Van Cutsem, E., Yoshino, T., Yaeger, R., Wasan, H., Desai, J., . . . Kopetz, S. (2023). Clinical … Read More
